The deal, which is expected to complete this month, will bring with it Diatherix’ capabilities in DNA and RNA testing, which are used by 7,000 healthcare professionals for diagnostics and sample analysis.
Eurofins CEO Gilles Martin said: “Diatherix strengthens Eurofins’ growing footprint in the specialty clinical diagnostics market, with truly unique and innovative services with high positive impact for patient care.
Biopharma focus
News of the deal comes just over a year after Eurofins bought ViraCor-IBT Laboratories, a specialist in biomarker analysis for hospitals and biopharmaceutical companies and is part of the same expansion strategy according to Martin.
“This acquisition reflects our strategy of expanding and strengthening our network of competence centers. In combination with ViraCor and Boston Heart, Diatherix reinforces the Group’s position in genetic testing to better serve the global healthcare community.”
It also follows two months after Eurofins' bioanalytical services arm launched an immunoassay service for biopharma developers.
Pall and Selvita have also recently invested in their bioassay platforms for large molecule drug development services.
Bio-outsourcing is on the rise, reports show, with analytical testing – such as assays – topping the list of tasks pharma companies and healthcare providers are willing to send out of house.